AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform for functional gene discovery and mapping out specific pathways underlying central nervous system diseases. By harnessing these capabilities, AGY identified potential target proteins that can be modulated to block the progression of the disease process. This is paving the way for novel CNS therapeutics and future growth for AGY. February 2, 2005

AGY Therapeutics to Present at International Stroke Conference. >>

Other News:

July 20, 2004
AGY Therapeutics Licenses Product Candidate from M's Science for Phase 2 Clinical Development. >>
©2004 AGY Therapeutics Inc. All rights reserved.